Most Sustainable Pharma and Biotech Companies in 2026, According to Corporate Knights

Key Takeaways

• Novonesis rose to 8th place, achieving 67% GHG cut since 2018
• Eisai’s renewable energy use hit 176,000 MWh in FY2024
• Novo Nordisk targets net‑zero value‑chain by 2045, 33% Scope 3 cut by 2033
• Sustainable revenue momentum now accounts for one‑third of Global 100 scores
• Pharma ESG scores influence access to capital and regulatory scrutiny

Pulse Analysis

The 2026 Global 100 from Corporate Knights marks a turning point for the life‑sciences sector, shifting the sustainability conversation from isolated emissions metrics to a broader view of product‑level impact. By weighting "sustainable revenue momentum" at 33% of the overall score, the ranking rewards companies that can rapidly scale low‑carbon therapies, biologics and industrial biotech solutions. This metric reflects investor appetite for growth tied to climate‑positive offerings, and it forces firms to disclose how quickly green revenues are expanding relative to traditional lines.

Novonesis A/S exemplifies the biotech‑driven pathway, leveraging enzymes and microbial platforms to replace fossil‑intensive chemicals. Its 67% reduction in Scope 1‑2 emissions, 100% renewable electricity and the restoration of 20 billion liters of water underscore a circular model that resonates with both investors and supply‑chain partners. Eisai Co Ltd, while maintaining a strong pharmaceutical pipeline, has accelerated renewable electricity consumption to 176,000 MWh and cut Scope 2 emissions to a few thousand tonnes of CO₂, illustrating how legacy drugmakers can retrofit sustainability into existing operations. Novo Nordisk A/S, a global leader in GLP‑1 therapies, pairs blockbuster growth with an ambitious "Circular for Zero" agenda, targeting net‑zero across its value chain by 2045 and a 33% reduction in Scope 3 emissions by 2033, while its 48.5% sustainable‑revenue momentum score signals that high‑margin products can be aligned with climate goals.

For the broader industry, these rankings send a clear message: ESG performance now directly influences financing terms, partnership eligibility and regulatory risk assessments. Companies that can demonstrate measurable, revenue‑linked sustainability—through renewable power, waste‑to‑resource loops, or low‑carbon product portfolios—will attract premium capital and enjoy greater market resilience. As investors and policymakers tighten climate‑related criteria, life‑science firms must integrate ESG metrics into strategic planning, supply‑chain contracts and R&D pipelines to stay competitive in a rapidly greening market.